Shenzhen Yinghe Brain Science Co., Ltd announced that it has received $14.800000 million in funding from Eli Lilly Investment Consulting Shanghai Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Beijing Enlight Media Co., Ltd., Xi'an Xijiao 1896 Capital Management Co., Ltd., Shenzhen Qianhai BangQin Investment Co., Ltd. and other investors.
January 29, 2023
Share
Shenzhen Yinghe Brain Science Co., Ltd announced that it has received $14,800,000 in angel round of funding led by Eli Lilly Investment Consulting (Shanghai) Co., Ltd. and Shenzhen Qianhai BangQin Investment Co., Ltd. on January 30, 2023. The transaction included participation from Shenzhen New Industries Biomedical Engineering Co., Ltd., Beijing Enlight Media Co., Ltd., and Xi'an Xijiao 1896 Capital Management Co., Ltd.
Shenzhen New Industries Biomedical Engineering Co Ltd is a company engaged in research and development, production and sales of in-vitro diagnostics instruments and supporting reagents. The Company operates three segments, including Instruments and Supporting Software, Reagents, Accessories and Others. Instruments and Supporting Software segment is involved in the production and sales of MAGLUMI automatic chemiluminescence immunoassay analyzer series products and Biossays automatic biochemical analyzer series products. Reagents segment operates the sales of supporting reagents for the analyzers. The products are applied in the examination of Gonads, thyroid gland, glucose metabolism, kidney function and so on. Accessories and Others segment is responsible for the manufacturing and sales of accessories related to in-vitro diagnostics equipment. The Company sells its products both in domestic and international markets, including Asia, Europe, America and Africa.
Shenzhen Yinghe Brain Science Co., Ltd announced that it has received $14.800000 million in funding from Eli Lilly Investment Consulting Shanghai Co., Ltd., Shenzhen New Industries Biomedical Engineering Co., Ltd., Beijing Enlight Media Co., Ltd., Xi'an Xijiao 1896 Capital Management Co., Ltd., Shenzhen Qianhai BangQin Investment Co., Ltd. and other investors.